Bothrops asper snake venom toxins

Bothrops asper snake venom toxins comprise a complex mixture of proteins and peptides that serve as the primary pathological agents in envenomations by the Terciopelo snake, the most medically significant species in Central America (Gutiérrez et al., 2009). The venom is dominated by snake venom metalloproteinases (SVMPs) and phospholipases A2 (PLA2s), which together account for the majority of its toxic effects, including severe hemorrhage, myonecrosis, and edema (Alape-Girón et al., 2008). SVMPs act by degrading the basement membrane of capillary vessels, leading to systemic bleeding, while PLA2s disrupt cell membranes and induce muscle tissue death (Gutiérrez et al., 2009). Other components such as serine proteinases and L-amino acid oxidases further complicate the clinical picture by inducing coagulopathy and systemic inflammatory responses (Angulo & Lomonte, 2009). Current treatment relies on polyvalent antivenoms that contain antibodies designed to bind and neutralize these diverse toxins. However, the rapid onset of local tissue damage often limits the effectiveness of antivenom, prompting the investigation of small-molecule inhibitors like varespladib and marimastat as adjunct therapies (Elife, 2026). These inhibitors target specific toxin families to prevent the progression of permanent physical disability and life-threatening systemic complications.

Other names

Terciopelo venom toxinsBarba amarilla venom toxinsBothropic venom toxinsBothrops asper venom proteins

Antibody-mediated neutralization of venom antigens; competitive inhibition of phospholipase A2 enzymes; chelation of zinc ions in metalloproteinases; inhibition of serine protease activity.